Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 20-Strain pneumonia vaccine trial launches in china

NCT ID NCT07023081

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new vaccine that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other infections. Around 200 healthy Chinese adults, children, and infants will receive the vaccine to see if it is safe and how well it triggers an immune response. The vaccine is given in different doses depending on age, and participants are monitored for side effects over several months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

200 people

The number who actually took part.

Started

Jun 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

42 days to 49 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: * Male or female participants: * Adults ≥18 to \<50 years of age * Children ≥2 to \<6 years of age * Children ≥12 months to \<2 years of age * Infants ≥7 to \<12 months of age * Infants ≥42 to ≤98 days of age * Healthy participants determined by clinical assessment and clinical judgment, to be eligible for the study. Key exclusion criteria: * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention, or any diphtheria toxoid-containing vaccine. * History of microbiologically proven invasive disease caused by S pneumoniae. * Congenital, functional, or surgical asplenia. * Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation. * Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s). Please refer to the study contact for further eligibility details.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal disease

Contacts and locations

Locations

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    Nanning, Guangxi, 530021, China

  • Wuming District Center for Disease Control and Prevention

    Chengxiang, Nanning, 530199, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.